Glutalor Medical announces one of its US patent applications related to its glucose CGM (continuous glucose monitoring) technology has been granted. Their patent application ” Dynamic Blood Glucose Data Acquiring Device and Host” was granted in Oct 2020. This new patent strength Glutalor’s glucose monitoring patent portfolio.
Glutalor Medical announces one of its EU Patent applications related to its glucose CGM (continuous glucose monitoring) technology has been granted. Their patent application ” CONTINUOUS GLUCOSE MONITORING SYSTEM AND MONITORING TERMINAL” was granted in June 2020. This new patent adds to Glutalor’s glucose monitoring patent portfolio which two CGM Read more…
Glutalor Medical Announces ISO 13485 Certification for Its CGM Sensor Manufacture EXTON, PA. (PRWEB) JUNE 11, 2020 Glutalor Medical, a medical technology company focused on the development and manufacturing of continuous glucose monitoring devices (CGM), announced today that the Company has satisfied the requirements for ISO 13485 certification for its medical Read more…
Glutalor Medical Exhibits its iWel Mobile Glucose CGM Platform at the ADA (American Diabetes Association) Annual Conference in San Francisco
Glutalor Medical showcases its glucose CGM (continuous glucose monitoring) portfolio products at the 79th American Diabetes Association (ADA) scientific session at the Mascone Center, San Francisco, CA from June 7 to 11, 2019.
Glutalor exhibits its iWel mobile continuous glucose monitoring (CGM) platform products at ADA 2018 in Orlando, Florida
With continuous glucose monitoring systems (CGM) become more insurance covered, more affordable and better accuracy, more and more diabetic patients are using glucose CGM because of its great benefits,
Glutalor Medical to exhibit its iWel Continuous Glucose Monitoring (CGM) product at the annual American Diabetes Association meeting to be held at New Orleans, Louisiana in June 2016. Its iWel CG2 CGM device, an improved CGM product, is under filing for European approval.